All In Biotech

Free tool

FAERS Monitor: Camcevi Etm

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219745 or its brand name (Camcevi Etm, Leuprolide Mesylate). Reports on generic versions are filed under their own applications.

Reports

1,547

Serious

1,095

71% of reports

Hospitalization

513

Death reported

129

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective117
  • fatigue93
  • off label use90
  • nausea79
  • headache68
  • malignant neoplasm progression62
  • disease progression56
  • vomiting49
  • febrile neutropenia48
  • product storage error45
  • product use in unapproved indication41
  • anaemia39
  • dyspnoea39
  • pain39
  • acute kidney injury38

Reports by year received

View as table
YearReports
20052
20063
20116
20127
201327
201431
201531
201630
201762
201894
2019151
2020126
2021140
2022126
2023135
2024142
2025229
2026205

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,612 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal489.87.5374
malignant neoplasm progressionSignal628.26.5389
product storage errorSignal457.05.2226
disease progressionSignal566.45.0253
acute kidney injurySignal383.42.562
anaemiaSignal392.82.043
product use in unapproved indicationSignal412.21.728
fatigue931.61.323
headache681.51.210
vomiting491.41.16
off label use901.41.110
nausea791.41.17
drug ineffective1171.21.04
dyspnoea390.90.70
pain390.90.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.